Company Encyclopedia
View More
name
LAEKNA-B
02105.HK
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE122, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. It has a collaboration with Eli Lilly and Company for the development of LAE102.
1.294 T
02105.HKMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking25/54
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-34.59%E
    • Profit Margin-5191.85%E
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY605.33%A
    • Net Profit YoY18.59%B
    • Total Assets YoY14.09%B
    • Net Assets YoY7.38%B
  • Cash ScoreB
    • Cash Flow Margin-1.93%D
    • OCF YoY605.33%A
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio21.96%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Top 10 HK Stock Losers (12.22)

    JACOBIO-B(01167) fell 13.58%, with a trading turnover 196.1 Million HKD, and a year-to-date rose 516.5%. SEYOND(02665) fell 10.48%, with a trading turnover 7.8 Million HKD, and a year-to-date rose 29%. LAEKNA-B(02105) fell 8.94%, with a trading turnover 60.6 Million HKD, and a year-to-date rose 50.1%.

    Top Gainers & Losers·
    HK
    01167
    -13.58%
    HK
    02665
    -10.48%
    HK
    02105
    -8.94%
    Top Gainers & Losers·
    HK
    01167
    -13.58%
    HK
    02665
    -10.48%
    HK
    02105
    -8.94%

    Hong Kong Stock Movement: LAEKNA-B surged 15.25%, with active capital flow attracting market attention

    LAEKNA-B rose 15.25%; CanSino Biologics rose 5.14%, with a transaction volume of HKD 1.006 billion; Innovent Biologics rose 1.84%, with a transaction volume of HKD 825 million; BeiGene fell 0.49%, with a transaction volume of HKD 515 million; Kelun-Biotech rose 0.49%, with a market value of HKD 106.2 billion

    HK Stock Movers Tracker·
    HK
    02105
    -8.94%
    HK Stock Movers Tracker·
    HK
    02105
    -8.94%

    Muscle Gain BIC, Space Opens Up

    LAEKNA-B has made significant progress in the field of fat reduction and muscle gain. Phase I clinical MAD studies show that patients in the 6mg/kg dosage group experienced an average lean body mass increase of 1.7% and a fat mass reduction of 2.2% by the fifth week. The drug has demonstrated excellent medication adherence and safety, with the potential to become best in class. The global weight loss market is active, and the success of LAE102 could bring surprises to the market

    Zhitong·
    HK
    02105
    -8.94%
    Zhitong·
    HK
    02105
    -8.94%

    In the weight loss sector, will LAEKNA become the biggest winner with the next heavyweight BD?

    The weight loss sector is becoming an important variable in the global pharmaceutical industry, attracting the attention of many pharmaceutical giants. Pfizer's acquisition of the biotech company Metsera for $7.3 billion demonstrates the active merger and acquisition trend in this field. China's LAEKNA has also made progress in the development of weight loss drugs, with its ActRII monoclonal antibody LAE102 showing potential for muscle gain and fat loss, as well as good safety in Phase I clinical trials, possibly becoming a future winner

    Zhitong·
    HK
    02105
    -8.94%
    US
    PFE
    +0.60%
    Zhitong·
    HK
    02105
    -8.94%
    US
    PFE
    +0.60%

    Understanding the Market | LAEKNA-B rises over 6% again, accumulating a 36% increase over the past three trading days. Positive preliminary results from Phase I clinical MAD study

    LAEKNA-B's stock price rose over 6% again, with a cumulative increase of 36% over the past three trading days, reporting HKD 17.55 as of the time of writing, with a transaction volume of HKD 118 million. The company's LAE102 has achieved positive preliminary results in its Phase I clinical MAD study targeting obesity, showing a trend of muscle gain and fat loss. Analysts believe that bimagrumab's withdrawal from diabetes trials has weakened potential competition and enhanced LAE102's market value. DBS has reiterated a "Buy" rating, expecting subsequent data to spark interest in collaboration

    Zhitong·
    HK
    02105
    -8.94%
    Zhitong·
    HK
    02105
    -8.94%
    © 2025 Longbridge｜Disclaimer